A Pilot Trial to Investigate the Safety and Efficacy of Intestinal Microbiome Transplant (MTT) in People With Amyotrophic Lateral Sclerosis
This is a 24-week study of intestinal microbiome transplant in people with ALS. All participants will be evaluated clinically in person for 4 visits. Blood and mailed/ fresh stool samples will also be collected. Blood samples will be used to determine changes in neurofilament light chain over time. Stool samples will be processed for microbiome analysis. Participants will have phone visits to further evaluate safety and tolerability. They will then undergo antibiotic conditioning and a standard bowel preparation before being assigned to the investigational product, MTP-101C .
• Diagnosis of ALS according to Gold Coast Criteria
• Age: 18+ years at enrollment
• Fast-progressing (ALSFRS-R change of at least 1.5 points per month between last 2 measurements at screening)
• Modestly but not severely affected (ALSFRS-R score at or above 24 at screening)
• Able to swallow capsules and expected to be able to for the duration of the trial (ALSFRS-R swallowing score of 3 or 4 at screening)
• Expected to survive for the duration of the trial
• Taking any combination of riluzole, edaravone, and/or tofersen at a stable dose for 30 days prior to screening, or not taking any of these and not expected to during the study.
• Capable of giving written consent.
• If sexually active, must agree to use contraceptive or abstinence for duration of treatment.
• Females of child-bearing age must have negative pregnancy test at screening.